Flynn James E 13D and 13G filings for Prelude Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 08:58 am Sale |
2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 0 0.000% |
-4,133,000 (Position Closed) |
Filing |
| 2024-02-12 5:30 pm Purchase |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 4,133,000 9.850% |
910,310 (+28.25%) |
Filing |
| 2023-11-13 08:30 am Purchase |
2023-11-02 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 3,222,690 7.680% |
3,222,690 (New Position) |
Filing |